BCellOne Secures CHF 100,000 FIT Innogrant
© 2024 EPFL
BCellOne unveils cutting-edge transfection system for enhanced cell and gene therapies and secures CHF 100,000 from the Foundation for Technological Innovation (FIT) to further develop its technology.
Stemming from EPFL, the BCellOne project has been awarded a CHF 100,000 FIT InnoGrant. This new-generation transfection system promises to revolutionise the field of cell and gene therapies, the very treatments that are shaping the future of personalised medicine.
By using a substantially low-intensity electric field, BCellOne offers a gentler and more efficient transfection method, improving cell viability and efficiency. This technology positions BCellOne as a solution of choice for biotechnology companies and researchers in the field of cell and gene therapy.
More information about the startups in creation at EPFL.